Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients

Trial Profile

Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs VL 2397 (Primary) ; Amphotericin B liposomal; Isavuconazole; Voriconazole
  • Indications Aspergillosis
  • Focus Therapeutic Use
  • Sponsors Vical
  • Most Recent Events

    • 30 Oct 2017 Status changed from planning to not yet recruiting.
    • 05 Oct 2017 According a Vical media release, antifungal VL-2397 is eligible for limited use indication approval by FDA based on this Phase II efficacy trial.
    • 05 Jun 2017 According a Vical media release, company is planning to initiate this trial in fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top